Skip to content

Study · Animal study (in vivo) · mouse · 1998

3 results

[The anxiolytic action of an analog of the endogenous peptide tuftsin on inbred mice with different phenotypes of the emotional stress reaction].

Seredenin SB, Kozlovskaia MM, Blednov IuA, Kozlovskiĭ II, Semenova TP, Czabak-Garbacz R, Nezavibat'ko VN, Miasoedov NF

Zhurnal vysshei nervnoi deiatelnosti imeni I P Pavlova1 Jan 1998Cited by 8 (Europe PMC)

PMID9583175 (opens in a new tab)PepBankPUB-09583175
Publisher pageAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In Balb/c mice with a high level of anxiety, intraperitoneal Selank prevented manifestations of anxiety in stress tests over a wide dose range.

    In plain wordsIn anxious mice of one strain, Selank prevented signs of anxiety in behaviour tests.

    Peptide
    Selank
    Outcome
    DecreaseAnxiety in Balb/c mice (open field, elevated plus-maze, light-dark chamber)
    Study

    mousen: not reported in source

    inbred Balb/c and C57Bl/6 mice with different emotional-stress reaction types
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    200-3000 mcg/kg · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    the heptapeptide prevented manifestations of anxiety being administered intraperitoneally in a wide range of active doses (200-3000 mcg/kg)
    1 context sentence
    Summary · context
    The anxiolytic effect of the synthetic analogue of the endogenous peptide tuftsin (Thr-Lys-Pro-Arg-Pro-Gly-Pro) was studied in inbred mice Balb/c (C) and C57B1/6 (B6) with different heritable types of emotional-stress reaction.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In C57Bl/6 mice with a low level of anxiety, Selank did not change behaviour.

    In plain wordsIn mice of a low-anxiety strain, Selank did not change behaviour.

    Peptide
    Selank
    Outcome
    No significant changeBehaviour of C57Bl/6 mice with low anxiety
    Study

    mousen: not reported in source

    inbred Balb/c and C57Bl/6 mice with different emotional-stress reaction types
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The drug did not change the behaviour of B6 mice with low level of anxiety and active type of emotional-stress reaction.
    1 context sentence
    Summary · context
    The anxiolytic effect of the synthetic analogue of the endogenous peptide tuftsin (Thr-Lys-Pro-Arg-Pro-Gly-Pro) was studied in inbred mice Balb/c (C) and C57B1/6 (B6) with different heritable types of emotional-stress reaction.
  3. 03AnimalAnimal study (in vivo)Safety outcome

    In mice, Selank had no side inhibitory behavioural effects, even in high doses.

    In plain wordsIn mice, Selank did not cause the side effects on behaviour that were reported for benzodiazepines, even at high doses.

    Peptide
    Selank
    Outcome
    No significant changeSide inhibitory behavioural effects
    Study

    mousen: not reported in source

    inbred Balb/c and C57Bl/6 mice with different emotional-stress reaction types
    Outcome group
    Adverse events · Mental health and mood
    Studied dose
    Dose not stated

    Source sentences

    Summary
    the heptapeptide has no side inhibitory behavioural effects even in high doses.
    1 context sentence
    Summary · context
    The anxiolytic effect of the synthetic analogue of the endogenous peptide tuftsin (Thr-Lys-Pro-Arg-Pro-Gly-Pro) was studied in inbred mice Balb/c (C) and C57B1/6 (B6) with different heritable types of emotional-stress reaction.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 17:28 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.